Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Shares Outstanding (2016 - 2025)

Traws Pharma (TRAW) has disclosed Shares Outstanding for 10 consecutive years, with $6737.0 as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding fell 9.45% to $6737.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $6737.0, a 9.45% decrease, with the full-year FY2024 number at $3.7 million, up 334.48% from a year prior.
  • Shares Outstanding was $7.1 million for Q3 2025 at Traws Pharma, up from $7.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $7.1 million in Q3 2025 to a low of $7398.0 in Q4 2024.
  • A 5-year average of $1.4 million and a median of $470870.0 in 2021 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: soared 737.04% in 2022, then tumbled 99.33% in 2025.
  • Traws Pharma's Shares Outstanding stood at $100000.0 in 2021, then skyrocketed by 737.04% to $837040.0 in 2022, then rose by 0.38% to $840251.0 in 2023, then skyrocketed by 334.48% to $3.7 million in 2024, then crashed by 99.82% to $6737.0 in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Shares Outstanding are $6737.0 (Q3 2025), $6737.0 (Q2 2025), and $7398.0 (Q1 2025).